Complete FDA and NHTSA recall records dated in 2025, organized for browsing by month, category and recalling company.
Select a month to review the recall records reported during that period.
Records are ordered by the best available source date.
Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.
Subpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.
BMW of North America, LLC (BMW) is recalling certain 2025 X3 30 xDrive vehicles. The connection between the positive battery cable and the starter-generator may have been improperly…
BMW of North America, LLC (BMW) is recalling certain 2022-2024 X3 sDrive30i and X3 xDrive30i vehicles. The second-row seat side door locking modules may not function properly and allow the…
Tesla, Inc. (Tesla) is recalling certain 2023 Model 3 and Model Y vehicles operating software prior to 2023.38.4. The printed circuit board for the electronic power steering assist may…
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin (epinephrine injection, USP)
Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
Failed Dissolution Specifications.
CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.
General Motors, LLC (GM) is recalling certain 2022 GMC Sierra 1500 vehicles equipped with chrome front grille deflectors. The attachments that hold the front grille deflectors in place may…
Honda (American Honda Motor Co.) is recalling certain 2025 Honda Pilot vehicles. The third-row passenger seat belt assembly may not function, due to incorrect routing that traps the seat…
Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
cGMP Deviations: Product intended for quarantine was inadvertently distributed.
CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit
Labeling: Missing Label: The finished product potentially missing the labeling with the drug facts panel, bar code and directions for use.
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.
